Retifanlimab-Dlwr
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 7 publications
An evaluation of retifanlimab-dlwr with carboplatin and paclitaxel and as a single agent for squamous cell carcinoma of the anal canal.
Journal: Expert review of anticancer therapy
Published: July 22, 2026
Retifanlimab (Zynyz) for anal cancer.
Journal: The Medical letter on drugs and therapeutics
Published: July 12, 2025
Updates in the Management of Advanced Nonmelanoma Skin Cancer.
Journal: Surgical oncology clinics of North America
Published: September 07, 2024
Retifanlimab-dlwr.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Published: May 31, 2023
In brief: Retifanlimab (Zynyz) for Merkel cell carcinoma.
Journal: The Medical letter on drugs and therapeutics
Published: April 11, 2023
Showing 1-7 of 7
Last Updated: 09/26/2026